CLN-0500
Aug 24 2021
A Randomized, Parallel-Arm, Active Control, Multicenter Study Assessing the Safety and Efficacy of Dextenza for the Treatment of Ocular Pain and Inflammation Following Surgery for Pediatric Cataract Sponsor: Ocular Therapeutix, Inc. Principal Investigator: Michael Struck…
Read MoreUNITY
Aug 24 2021
A Phase 2a, Prospective, Multicenter, Randomized, Double-Masked, Sham-Controlled Study to Assess the Safety, Tolerability and Evidence of Activity of a Single Intravitreal Injection of UBX1325 in Patients with Diabetic Macular Edema Sponsor: UNITY Biotechnology, Inc.…
Read MorePEP
Aug 24 2021
Patient Experience and Preference (PEP) Study in nAMD and DME Sponsor: Hoffmann-La Roche Ltd
Read MoreMAC TEL
Dec 01 2020
Extension Study of NT-501 Ciliary Neurotrophic Factor (CNTF) Implant for Macular Telangiectasia (Mac Tel) Sponsor: Neurotech Pharmaceuticals, Inc. clinicaltrials.gov
Read MoreCATALINA
Dec 01 2020
A Phase II Multicenter, Randomized, Double-Masked, Sham-Controlled Study of the Safety and Efficacy of Intravitreal Injections of NGM621 in Subjects with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD) (CATALINA) Sponsor: NGM Biopharmaceuticals, Inc.…
Read MoreAGTC A3
Sep 30 2020
A Multiple-Site, Phase 1/2, Safety and Efficacy Trial of AGTC 402, a Recombinant Adeno-associated Virus Vector Expressing CNGA3, in Patients with Congenital Achromatopsia Caused by Mutations in the CNGA3 Gene Sponsor: Applied Genetic Technologies Corp…
Read MoreAGTC B3
Sep 30 2020
A Multiple-Site, Phase 1/2, Safety and Efficacy Trial of a Recombinant Adeno-associated Virus Vector Expressing CNGB3 (rAAV2tYF-PR1.7-hCNGB3) in Patients with Congenital Achromatopsia Caused by Mutations in the CNGB3 Gene Sponsor: Applied Genetic Technologies Corp visit…
Read MoreNIGHT
Sep 30 2020
Natural History of the Progression of Choroideremia Study (NIGHT) Sponsor: NightstaRx Ltd, a Biogen Company CLINICALTRIALS.GOV
Read More